IRF1 and neoplasm: Supplementation of 4-OI in IRF1 KO cells rescued thimerosal-induced tumor immunogenicity (Appendix Fig. S4E), indicating that defective itaconate production is responsible for the impaired immunogenicity of IRF1 KO cells.